1110 related articles for article (PubMed ID: 31206626)
1. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
2. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
5. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
[TBL] [Abstract][Full Text] [Related]
6. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes.
Singh K; Scalia J; Legare R; Quddus MR; Sung CJ
Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781
[TBL] [Abstract][Full Text] [Related]
8. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
[TBL] [Abstract][Full Text] [Related]
9. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
[TBL] [Abstract][Full Text] [Related]
10. Rare, protein-truncating variants in
Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF
J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
12. Germline testing of
Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
[TBL] [Abstract][Full Text] [Related]
13. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
14. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.
Kleibl Z; Kristensen VN
Breast; 2016 Aug; 28():136-44. PubMed ID: 27318168
[TBL] [Abstract][Full Text] [Related]
15. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
16. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
[TBL] [Abstract][Full Text] [Related]
18. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC
Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310
[TBL] [Abstract][Full Text] [Related]
19. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W
Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]